Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canakinumab - Novartis

Next Previous
X
Search
Drug Profile

Canakinumab - Novartis

Alternative Names: ACZ-885; Anti-IL-1 beta monoclonal antibody; Antibody A; Ilaris

Latest Information Update: 22 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Charite - Universitatsmedizin Berlin; Columbia University; Novartis; Triemli hospital; University Hospital Tubingen; University Hospital Zurich
  • Class Anti-inflammatories; Antianaemics; Antigouts; Antihyperglycaemics; Antineoplastics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Heart failure therapies; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial Mediterranean fever; Pancreatic cancer; Juvenile rheumatoid arthritis; Inflammation; Cryopyrin-associated periodic syndromes; Peroxisomal disorders; Familial autosomal dominant periodic fever; Adult-onset Still's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adult-onset Still's disease; Cryopyrin-associated periodic syndromes; Familial autosomal dominant periodic fever; Familial Mediterranean fever; Gouty arthritis; Juvenile rheumatoid arthritis; Peroxisomal disorders
  • Preregistration Cardiovascular disorders
  • Phase III Behcet's syndrome; COVID 2019 infections; COVID-19 pneumonia; Cytokine release syndrome; Non-small cell lung cancer
  • Phase II Abdominal aortic aneurysm; Alcoholic hepatitis; Alzheimer's disease; Atherosclerosis; Heart failure; Malignant melanoma; Mild cognitive impairment; Myelodysplastic syndromes; Osteoarthritis; Peripheral arterial occlusive disorders; Pulmonary sarcoidosis; Respiratory insufficiency; Schnitzler syndrome; Sickle cell anaemia
  • No development reported Chronic obstructive pulmonary disease; Pancreatic cancer; Renal cell carcinoma; Triple negative breast cancer
  • Discontinued Asthma; Diabetic retinopathy; Polymyalgia rheumatica; Rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 09 Aug 2024 Novartis terminates a phase-II trial in Osteoarthritis in USA, Czechia, Estonia, Germany, Hungary, Latvia, Lithuania and Poland, due to sponsor decision (Intra-articular, Injection) (NCT04814368) (EudraCT2020-003631-21)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, Second-line therapy or greater) in Australia (SC)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, Second-line therapy or greater) in Israel (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top